Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a dual PAK4/NAMPT inhibitor for the...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of 6996.HK is 3.0 and suggests 15% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
Buy
Sell